Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Healthy Volunteers
Interventions: PF-07976016 Formulation A, PF-07976016 Formulation B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Caries
Interventions: 0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control); Drug
Lead sponsor: Domenick Zero; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Varicella, Rubella, Mumps, Measles
Interventions: Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 14 Months
Enrollment: 1,851 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 141
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more

Conditions: Healthy
Interventions: IVX-121, IVX-241, Placebo, MF59®; Biological · Other
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more

Conditions: Immune System and Related Disorders, Immune System Diseases
Interventions: Cannabidiol (CBD); Dietary Supplement
Lead sponsor: NextEvo Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cushings Disease, Cushing Disease
Interventions: LCI699; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Healthy
Interventions: PF-05221304 Formulation A, PF-05221304 Formulation B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: MK-0616A, Enlicitide, Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions: alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more

Conditions: Coronary Restenosis
Interventions: TAXUS Express2, Brachytherapy (beta source); Device · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 40
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 35 more

Conditions: Depression
Interventions: generic bupropion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Interventions: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Post-traumatic Osteoarthritis of the Knee
Interventions: FX006 32 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypercholesterolemia
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metabolism of Prostaglandin D2
Interventions: niacin, aspirin, PGD2; Dietary Supplement · Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions: Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Nutriceutical formulation, Placebo; Dietary Supplement · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 40 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more

Conditions: Pain
Interventions: VX-548; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity
Interventions: Lorcaserin hydrochloride; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Hypoglycemia
Interventions: Glucagon for Injection (Fresenius Kabi USA), Glucagon for Injection (Bedford Laboratories); Drug
Lead sponsor: Fresenius Kabi USA, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Tofacitinib tablet, Tofacitinib Oral Solution; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Olomorasib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Parkinson's Disease, Freezing of Gait, Cognitive Ability, General
Interventions: Droxidopa, sugar pill; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 30 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • West Bloomfield, Michigan

Conditions: Acute Post Operative Pain, Third Molar Extraction Surgery
Interventions: ARC-001, Placebo gel; Drug
Lead sponsor: Arcato Laboratories, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Study of Cannabidiol (CBD) in Healthy Volunteers

Safety and Efficacy of LCI699 in Cushing's Disease Patients

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet

Pathways of Eicosanoid Metabolism

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction